[FBT] First Trust NYSE Arca Biotchnlgy Indx Fd

Overview

Type of security: Fund

Tags: Biotech, Country, Equity, ETF, Health, Health care, Healthcare, Index Based, Not Inversed, Sector, Stocks, U.S., Unleveraged

The data is delayed by 15 minutes.

 

Price: 94.03 Change: 2.06 (2.24%)
Ext. hours: Change: 0 (0%)

chart FBT

Refresh chart

Strongest Trends Summary For FBT

FBT is in the long-term up 65% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

See how to gain 20% in 14 sec with TrendsInvesting

Technical Data
High 52 week157.45 Low 52 week113.75 Last close156.12 Last change-0.72%
RSI65.2 Average true range2.03 Beta0.9 Volume96.28 K
Simple moving average 20 days2.32% Simple moving average 50 days4.59% Simple moving average 200 days13.18%
Performance Data
Performance Week0.45% Performance Month4.67% Performance Quart10.94% Performance Half12%
Performance Year25.09% Performance Year-to-date25.33% Volatility daily0.98% Volatility weekly2.19%
Volatility monthly4.5% Volatility yearly15.58% Relative Volume226.58% Average Volume111.91 K
New High New Low
Funds Characteristics
30-day SEC yield Average market capitalization Average weighted market capitalization Forward P/E
Gross expense ratio0.6% Index dividend yield Median market cap7.9 B Number of holdings20
Price to Book Value 6.71 Price to Earnings34.23 Total expense ratio Total net assets
Weighted market capitalization

Info

Characteristics:
NAME VALUE
Gross Expense Ratio0,6
Number Of Holdings20
Maximum Market Cap111.03 billion
Median Market Cap7.90 billion
Minimum Market Cap1.09 billion
P/E Ratio34,23
P/Bv Ratio6,71
P/Cf Ratio26,43
P/S Ratio9,51
Top Holdings:
NAME VALUE
Intermune, Inc.9,27
Myriad Genetics, Inc.6,77
Illumina, Inc.5,41
Alexion Pharmaceuticals, Inc.5,4
Cepheid, Inc.5,3
Amgen, Inc.5,14
Regeneron Pharmaceuticals, Inc.5,11
Exact Sciences Corp.4,9
Biogen Idec, Inc.4,89
Biomarin Pharmaceutical, Inc.4,61

News

2018-12-03 09:59:02 | Why Exelixis Stock Soared 46% in November

2018-11-29 16:45:02 | How BioMarin Pharmaceutical’s Financials Look in November

2018-11-20 14:03:48 | 7 Biotech ETFs to Consider for 2019

2018-11-06 16:20:02 | A Look at Exelixis’s Financials in November

2018-10-26 09:40:02 | Analysts Expect Incyte to Report Revenue Growth in Third Quarter

2018-10-25 12:01:41 | Alkermes in the Third Quarter: A Performance Overview

2018-10-09 09:01:01 | A Financial Overview of Ionis Pharmaceuticals in October

2018-10-04 07:31:14 | Ionis Pharmaceuticals’ Revenue Stream

2018-09-28 15:20:11 | How Vertex Pharmaceuticals Is Positioned Financially

2018-09-27 08:08:27 | Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

2018-09-20 12:29:10 | Top ETFs: First Trust Biotech Beats Larger Rivals

2018-09-06 17:05:02 | Estimates and Recommendations for Bluebird Bio on September 6

2018-08-31 15:12:40 | How Analysts View BioMarin Pharmaceutical in August

2018-08-22 13:25:02 | Incyte’s Revenue Stream in Q2 2018

2018-08-09 10:01:06 | Smaller Is Better For This Biotech Play Up More Than 20% In 2018

2018-08-06 08:06:21 | What Do Analysts Expect from Ionis’s Q2 2018 Earnings?

2018-08-02 12:55:00 | Adding Biotech ETFs to Your Portfolio

2018-07-31 14:09:17 | Incyte’s Q2 2018 Earnings Beat Analysts’ Revenue Estimates

2018-07-31 13:54:29 | Bluebird Bio’s Q2 2018 Earnings: Analysts’ Estimates

2018-07-24 12:05:00 | Chile’s Pension Risk Rating Commission Approves Sale of Additional First Trust ETF

2018-07-12 16:53:00 | 5 Safe and Sound ETF Strategies for 2H

2018-07-12 15:50:07 | What Investors Need to Know about Biotech ETFs

2018-07-06 13:50:51 | Biotech ETFs Climb on Biogen’s Promising Clinical Trial

2018-05-30 10:30:49 | Incyte’s Collaborations and Developments in Q1 2018

2018-05-25 10:33:07 | What Analysts Think about Ionis

2018-04-02 14:54:29 | Alkermes FDA Refusal: Biotech ETFs Dragged Down

2018-03-28 14:49:10 | Ionis Pharmaceuticals Stock as of March 27, 2018

2018-03-19 16:15:00 | The 4 Top Biotech ETFs

2018-03-09 15:45:00 | 9 ETF Winners From 9-Year Bull Run

2018-03-08 12:20:00 | 4 Hot Sector ETFs Springing Up to Rank #1

2018-03-07 10:49:03 | 4 Hot Sector ETFs Springing Up to Rank #1

2018-01-22 13:59:05 | Biotech ETFs Pop on Celgene, Juno Deal

2018-01-10 14:35:13 | A Look at Ionis Pharmaceuticals’ January 2018 Valuation

2017-12-07 10:09:03 | Sector ETF & Stock Winners 10-Years Since Great Recession

2017-10-30 16:55:00 | Chile’s Pension Risk Rating Commission Approves Sale of Four Additional First Trust ETFs

2017-10-11 16:47:00 | Four Additional First Trust ETFs Approved for Sale in Mexican Pension Plans

2017-09-21 14:13:18 | Gene-Editing Could Modify and Cure Disease: CRISPR vs. TALENs

2017-09-21 11:56:18 | A Shot in the Arm for the UK Life Sciences Industry?

2017-09-12 13:40:56 | Apple Gains As Launch Event Kicks Off; 2 Dividend Plays To Watch

2017-09-12 10:36:57 | How Gilead’s Other Products Performed in 2Q17

2017-09-11 12:55:40 | 2 Hot Biotech Plays In Reach, But Is Apple Still In Buy Range?

2017-09-08 14:01:32 | Nuplazid Expected to Become a Leading Central Nervous System Drug

2017-09-06 07:37:49 | Behind Bioverativ’s Analyst Recommendations This September

2017-08-23 18:06:44 | Ionis Reports Revenue Growth in 2Q17

2017-08-22 17:29:00 | ETF Topper: Biotechnology Isn't Totally on the Outs

2017-07-20 17:07:00 | ETF Topper: Biotech Stocks Break Out

2017-07-10 12:45:58 | The Rise of Amgen Stock in 2Q17

2017-07-04 10:37:39 | What Analysts Recommend for United Therapeutics in June 2017

2017-07-03 09:01:04 | Neurocrine Biosciences: Ingrezza, Collaborations, Ratings

2017-06-30 09:30:01 | The Zacks Analyst Blog Highlights: SPDR Technology ETF, SPDR S&P Biotech ETF, First Trust NYSE Arca Biotechnology Index Fund, BioShares Biotechnology Products ETF and SPDR Healthcare ETF